131 related articles for article (PubMed ID: 25428518)
1. Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon.
Falcini F; Rigante D; Candelli M; Martini G; Corona F; Petaccia A; La Torre F; Raffaele CG; Matucci Cerinic M
Clin Rheumatol; 2015 Jan; 34(1):167-9. PubMed ID: 25428518
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon.
Wollersheim H; Thien T; Hoet MH; Van Venrooy WJ
Eur J Clin Invest; 1989 Dec; 19(6):535-41. PubMed ID: 2515974
[TBL] [Abstract][Full Text] [Related]
3. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
Kallenberg CG
Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
[TBL] [Abstract][Full Text] [Related]
4. Outcome of positive antinuclear antibodies in individuals without connective tissue disease.
Myckatyn SO; Russell AS
J Rheumatol; 2003 Apr; 30(4):736-9. PubMed ID: 12672192
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease.
Vayssairat M; Baudot N; Gaitz JP
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):747-9. PubMed ID: 7722019
[TBL] [Abstract][Full Text] [Related]
6. Raynaud's features in childhood. Clinical, immunological and capillaroscopic study.
Navon P; Yarom A; Davis E
J Mal Vasc; 1992; 17(4):273-6. PubMed ID: 1494054
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's phenomenon as an early sign of connective tissue diseases.
Kallenberg CG
Vasa Suppl; 1992; 34():25-8. PubMed ID: 1529414
[TBL] [Abstract][Full Text] [Related]
8. Capillary microscopy is a potential screening method for connective tissue disease in children with Raynaud's phenomenon.
Farenhorst CA; Roon AM; Gessel AI; Stel AJ; Bootsma H; Armbrust W; Mulder DJ
Pediatr Rheumatol Online J; 2022 Feb; 20(1):11. PubMed ID: 35135560
[TBL] [Abstract][Full Text] [Related]
9. Associations of nailfold capillary abnormalities and immunological markers in early Raynaud's phenomenon.
Schlager O; Kiener HP; Stein L; Hofkirchner J; Zehetmayer S; Ristl R; Perkmann T; Smolen JS; Koppensteiner R; Gschwandtner ME
Scand J Rheumatol; 2014; 43(3):226-33. PubMed ID: 24517537
[TBL] [Abstract][Full Text] [Related]
10. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
[TBL] [Abstract][Full Text] [Related]
11. Prospective nailfold capillaroscopy evaluation of Raynaud's phenomenon in children and adolescents.
Piotto DG; Hilário MO; Carvalho NS; Len CA; Andrade LE; Terreri MT
Acta Reumatol Port; 2013; 38(2):114-21. PubMed ID: 24141348
[TBL] [Abstract][Full Text] [Related]
12. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
13. Nailfold capillaroscopic findings in primary Sjögren's syndrome with and without Raynaud's phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies.
Corominas H; Ortiz-Santamaría V; Castellví I; Moreno M; Morlà R; Clavaguera T; Erra A; Martínez-Pardo S; Ordóñez S; Santo P; Reyner P; González MJ; Codina O; Gelman MS; Juanola-Roura X; Olivé A; Torrente-Segarra V;
Rheumatol Int; 2016 Mar; 36(3):365-9. PubMed ID: 26597492
[TBL] [Abstract][Full Text] [Related]
14. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
15. Associations between nailfold capillary aberrations and autoantibodies in children and adults with Raynaud's phenomenon.
Mueller M; Gschwandtner ME; Emminger W; Kiener H; Schnaubelt S; Giurgea GA; Ristl R; Perkmann T; Koppensteiner R; Schlager O
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36972928
[TBL] [Abstract][Full Text] [Related]
16. Lung-dominant connective tissue disease among patients with interstitial lung disease: prevalence, functional stability, and common extrathoracic features.
Pereira DA; Dias OM; Almeida GE; Araujo MS; Kawano-Dourado LB; Baldi BG; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(2):151-60. PubMed ID: 25972968
[TBL] [Abstract][Full Text] [Related]
17. Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD).
De Angelis R; Cerioni A; Del Medico P; Blasetti P
Clin Rheumatol; 2005 Apr; 24(2):145-51. PubMed ID: 15351873
[TBL] [Abstract][Full Text] [Related]
18. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.
Moinzadeh P; Nihtyanova SI; Howell K; Ong VH; Denton CP
Clin Rev Allergy Immunol; 2012 Dec; 43(3):249-55. PubMed ID: 22711501
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammation predicts long-term mortality in patients with Raynaud's phenomenon.
Mueller M; Gschwandtner ME; Gamper J; Giurgea GA; Kiener HP; Perkmann T; Koppensteiner R; Schlager O
J Intern Med; 2018 Mar; 283(3):293-302. PubMed ID: 29068146
[TBL] [Abstract][Full Text] [Related]
20. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon.
Takehara K; Soma Y; Ishibashi Y
Dermatologica; 1991; 183(3):164-8. PubMed ID: 1743381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
